Loading...
Market
Ionis Pharmaceuticals' annual revenue increase by end of 2024?
5
Resolution / Starting Odds
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Ionis Pharmaceuticals' annual financial report
Story
Ionis Reports Positive Results for Donidalorsen in OASIS-HAE and OASISplus Trials
May 31, 2024, 03:02 PM
Ionis Pharmaceuticals has announced positive results from two late-stage trials, OASIS-HAE and OASISplus, for its investigational therapy donidalorsen in treating hereditary angioedema (HAE). The trials demonstrated that donidalorsen, which targets prekallikrein mRNA, significantly reduced the attack rate in patients compared to a placebo. These benefits were observed even in patients currently on other HAE medications. $IONS (-1.0% pre).
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5%-10% • 25%
10%-15% • 25%
More than 15% • 25%
Less than 10% increase • 25%
10% to 20% increase • 25%
20% to 30% increase • 25%
More than 30% increase • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Increase by 5-10% • 33%
Increase by 11-20% • 33%
Increase by more than 20% • 34%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Below $50 million • 33%
$50 million to $100 million • 33%
Above $100 million • 34%
Increase by over 30% • 25%
Increase by 20% to 30% • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Increase below 20% • 25%
20% to 40% increase • 25%
40% to 60% increase • 25%
Above 60% increase • 25%